

RESEARCH OUTPUTS / RÉSULTATS DE RECHERCHE

Impact of functional inorganic nanotubes f-INTs-WS2 on hemolysis, platelet function and coagulation

Laloy, Julie; Haguët, Hélène; Alpan, Lutfiye; Raichman, Daniel; Dogné, Jean-Michel; Lellouche, Jean-Paul

Published in:
Nano convergence

DOI:
[10.1186/s40580-018-0162-1](https://doi.org/10.1186/s40580-018-0162-1)

Publication date:
2018

Document Version
Publisher's PDF, also known as Version of record

[Link to publication](#)

Citation for published version (HARVARD):
Laloy, J, Haguët, H, Alpan, L, Raichman, D, Dogné, J-M & Lellouche, J-P 2018, 'Impact of functional inorganic nanotubes f-INTs-WS2 on hemolysis, platelet function and coagulation', *Nano convergence*, vol. 5, no. 1, 31.
<https://doi.org/10.1186/s40580-018-0162-1>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

Take down policy


If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

RESEARCH

Open Access



Impact of functional inorganic nanotubes f-INTs-WS₂ on hemolysis, platelet function and coagulation

Julie Laloy^{1,2*} , H       Haguet^{2,3} , Lutfiye Alpan^{1,2}, Daniel Raichman⁴, Jean-Michel Dogn  ^{1,2} and Jean-Paul Lellouche^{4*}

Abstract

Inorganic transition metal dichalcogenide nanostructures are interesting for several biomedical applications such as coating for medical devices (e.g. endodontic files, catheter stents) and reinforcement of scaffolds for tissue engineering. However, their impact on human blood is unknown. A unique nanomaterial surface-engineering chemical methodology was used to fabricate functional polyacidic polyCOOH inorganic nanotubes of tungsten disulfide towards covalent binding of any desired molecule/organic species via chemical activation/reactivity of this former polyCOOH shell. The impact of these nanotubes on hemolysis, platelet aggregation and blood coagulation has been assessed using spectrophotometric measurement, light transmission aggregometry and thrombin generation assays. The functionalized nanotubes do not induce hemolysis but decrease platelet aggregation and induce coagulation through intrinsic pathway activation. The functional nanotubes were found to be more thrombogenic than the non-functional ones, suggesting lower hemocompatibility and increased thrombotic risk with functionalized tungsten disulfide nanotubes. These functionalized nanotubes should be used with caution in blood-contacting devices.

Keywords: Functional tungsten disulfide nanotubes, Safety, Hemocompatibility, Thrombin generation

1 Introduction

Inorganic transition metal dichalcogenide (TMD) materials, such as tungsten and molybdenum disulfides (WS₂ and MoS₂, respectively) are of significant interest to the scientific community because of their unique multi-layered structures and functional properties, with nano-sized fullerene-like (IF) particles tending to exhibit a different set of properties compared to the corresponding bulk forms. These metal dichalcogenide nanomaterials have emerged as one of the most promising classes of nanomaterials since the discovery of carbon nanotubes (CNTs) [1–8]. As with early researches in the field of CNTs, a wide number of potential applications have been proposed and investigated including

areas such as energy storage [9], field effect transistors [10], nanocomposite coatings [11, 12], battery anodes [13], light-emitting diodes [14], self-lubricating medical devices [15], and high-performance nanoscale lubricants [16–23]. In addition, the outstanding shock absorbing ability of IFs-WS₂ nanotubes holds a great potential for new impact and shock-resistant materials [24–26]. Composite hybrid materials formed by incorporating small amounts (less than 5% weight ratios) of such nano-sized inorganic fillers into any given polymer matrix are also of particular interest, showing improved mechanical properties, higher thermal properties, and improved performances as barriers to heat, moisture, and solvents [27–29] when compared to similar composites prepared with conventional fillers [28, 30]. Indeed, considerable research work has been conducted dealing with polymer-based nanocomposites that incorporate inorganic IFs-WS₂ NPs into matrices of epoxy [30], polystyrene/poly(methylmethacrylate) [28], poly(propylene fumarate) [29], nylon 12 [31], and poly(phenylene) sulphide

*Correspondence: julie.laloy@unamur.be; lellouj@biu.ac.il

² Department of Pharmacy, NARILIS, University of Namur, Namur, Belgium

⁴ Department of Chemistry & Institute of Nanotechnology & Advanced Materials (BINA), Bar-Ilan University, Max & Anna Web Street, 5290002 Ramat-Gan, Israel

Full list of author information is available at the end of the article


[32]. Due to the superior mechanical properties of corresponding inorganic IFs-WS₂ NPs, such as high stiffness and strength [33], ultrahigh-performance polymer nanocomposites have been readily produced [34]. In addition, commercial performant lubricants are now presently available that include same inorganic IFs-WS₂ NPs that impart unique tribological properties [35] to the corresponding final composite products. Although there are many potential applications in a wide variety of fields for such inorganic metal dichalcogenide IFs-WS₂ NPs and inorganic INTs-WS₂ nanotubes (INTs), novel developmental research has been strongly hampered analogously to early CNTs-based research. Indeed, these dichalcogenide nanomaterials are highly hydrophobic, thus quite insoluble in common organic/aqueous solvents, difficult to homogeneously disperse into most liquids and resins, while disclosing serious limited dual phase compatibility when admixed with common polymers.

In this specific context, we recently developed a unique nanomaterial surface-engineering chemical methodology to fabricate covalently decorated functional polyacidic polyCOOH-INTs-WS₂ using Vilsmeier-Haack (VH) complex chemistry/reactivity (polyCOOH shell decoration) [36]. This novel surface engineering method enables effective covalent bonding of any desired molecule/organic species via polyCOOH shell chemical activation/reactivity that may improve and optimize any requested interfacial property of corresponding functional INTs-WS₂ (*f*-INTs-WS₂). This polycarboxylated shell can be readily exploited as an anchoring shell for subsequent second-step covalent attachment of a wide variety of organic molecules/polymers, including even other components such as NPs, for example, onto the functional nanotube surface. Therefore, a quite versatile simple organic activation chemistry (EDC•HCl activation of

polyCOOH shell/species) readily enables corresponding surface property tuning to match those requested for any contacting material (polymeric phases, solvents, etc.). Moreover and in this context, by employing appropriate bifunctional linkers such as those described in this study (obtainment of novel 2nd step polyNH₂/polySH/polyOH shells, Fig. 1), the resulting chemically modified *f*-INT-WS₂ can be covalently bound to an even wider variety of reactivity-complementing materials.

Recent progress in studies of this original novel class of inorganic nanomaterials suggests that they can be also impregnated into metallic coatings for medical administration/application [37]. For example, it was demonstrated that the use of orthodontic wires coated with metallic films containing IFs-WS₂ NPs in dentistry could significantly reduce the mechanical forces required for teeth realignment, thus preventing unnecessary excess forces that would lead to unacceptable teeth movement, longer treatment, and adverse damage to the roots of the teeth [10, 37, 38].

Since both IFs-WS₂ NPs and INTs-WS₂ are already commercially available in the market thus providing effective potentialities of incorporation/involvement towards innovative future medical applications, extensive research investigations concerning the overall biocompatibility and toxicity of these inorganic materials need to be performed to ensure that they are safe for composite-based usage. Researches on the toxicity of TMD nanomaterials is still in its infancy with only a handful of assessments performed on IFs-MoS₂ and IFs-WS₂ NPs. Preliminary results from in vivo toxicology tests of IFs-WS₂ NPs showed no apparent toxic effects on mammals, suggesting its high biocompatibility [39]. In addition, in vitro cytotoxicity examination of IFs-MoS₂ NPs on three different human cell lines (i.e. CCC-ESF-1,



A549, and K562) revealed that they are nontoxic to cells after 48 h exposure [17]. However, at the present time, no experimental studies assessed the hemocompatibility of TMD materials. With the influx of research and possible commercialization of TMDs in the future, it is vital to both initiate hemocompatibility studies of this group of nanomaterials and assess their impact on hemolysis, platelet functions, and blood coagulation [40].

In this special work, we characterized the hemocompatibility of such different functional INTs-WS₂ and assessed their impact on red blood cells, platelet aggregation and blood coagulation using human blood.

2 Methods

2.1 Materials

Non-functional INTs-WS₂ have been bought from Nano-Materials Ltd. Company (Yavne, Israel). All reagents and solvents have been purchased from commercial sources and used without any further purification. Thermogravimetric analyses (TGA) have been performed on a TA Q600-0348, model SDT Q600 (ThermoFinnigan) device using a temperature profile of 25–800 °C at 10 °C/min under nitrogen flow (180 mL/min) with sample amounts of 5–15 mg. Infrared (IR) spectra were recorded on a Fourier transform infrared spectrometer Tensor 27 (Bruker) using attenuated total reflectance (ATR). Nano-material surface charges were evaluated by ξ potential measurements using a Zetasizer Nano-ZS device (Malvern Instruments Ltd., United Kingdom) in water (pH adjusted) at 25 °C and 150 V. Both VH-untreated starting and resulting VH-modified *f*-INTs-WS₂ nanotubes have been also characterized using G2, FEI High Resolution transmission electron microscopy (TEM) (Tecnai). Dispersions of INT-WS₂ and *f*-INT-WS₂ have been prepared with a low-power ElmaSonic S30 bath sonicator (Elma GmbH & Co., Deutschland). The chemically accessible polyCOOH shell present on the surface of the polyCOOH *f*-INT-WS₂ has been also quantified by both (i) Kaiser testing after shell derivatization using 1,3-diaminopropane and (ii) Ellman's one after subsequent similar shell derivatization using cysteamine.

2.2 Polycarboxylation of INT-WS₂—fabrication of polyCOOH-*f*-INT-WS₂

To a solution of 2-bromoacetic acid (2-BrCH₂COOH), (1.0 g, 7.19 mmol) in anhydrous dimethyl formamide (DMF, 3 mL) was added Ag(I)OAc (10.0 mg, 0.059 mmol) and dry INT-WS₂ (200.0 mg). The mixture was heated in an oil bath to 80 °C and stirred over 2 days at the same temperature. After cooling to room temperature, the mixture was centrifuged (11,000 rpm, 5 min). The resulting cleaned (EtOH, 5 washing cycles) solids were dried

under vacuum to obtain 190 mg of functional polyCOOH *f*-INT-WS₂.

2.3 Diamine coupling onto polyCOOH *f*-INT-WS₂—fabrication of polyNH₂-*f*-INT-WS₂

To a solution of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC, 20.0 mg, 4 mmol) in dichloromethane (DCM, 12 mL) was added polyCOOH *f*-INT-WS₂ (200.0 mg) and 4-dimethylaminopyridine (DMAP, 10.0 mg, 0.08 mmol). The mixture was stirred for 2 h at room temperature followed by addition of 1,3-diaminopropane (NH₂-(CH₂)₃-NH₂, 800 μ L, 9.58 mmol) and stirring continued at room temperature overnight. The mixture was centrifuged (11,000 rpm, 5 min) and the supernatant discarded. The solids were worked up as described for former polyCOOH *f*-INT-WS₂. The product contained 0.77 mmol NH₂ groups/g of polyNH₂ *f*-INT-WS₂ as determined by Kaiser testing.

2.4 Cysteamine coupling onto polyCOOH *f*-INT-WS₂—fabrication of polySH-*f*-INT-WS₂

To a solution of EDC (3.0 g, 19.32 mmol) in DCM (40 mL) was added polyCOOH *f*-INT-WS₂ (1.8 g). The suspension was stirred for 2 h at room temperature followed by addition of cysteamine (NH₂-(CH₂)₂-SH, 4.0 g, 51.85 mmol) and DMAP (20.0 mg, 0.16 mmol) and stirring continued for 2 days at room temperature. The mixture was centrifuged (11,000 rpm, 5 min) and the supernatant discarded. The solids were worked up as described for former polyCOOH *f*-INT-WS₂ to obtain 1.6 g of functional product. The product contained 0.8 mmol SH groups/g of polySH *f*-INT-WS₂, as determined by Ellman testing.

2.5 2-Aminoethanol coupling onto polyCOOH *f*-INT-WS₂—Fabrication of polyOH-*f*-INT-WS₂

To a solution of EDC (3.0 g, 19.32 mmol) in DCM (40 mL) was added polyCOOH *f*-INT-WS₂ (1.5 g). The suspension was stirred for 2 h at room temperature followed by addition of 2-aminoethanol (NH₂-(CH₂)₂-OH, 4.0 mL, 64.71 mmol) and DMAP (20.0 mg, 0.16 mmol) and stirring continued for 2 days at room temperature. The mixture was centrifuged (11,000 rpm, 5 min) and the supernatant discarded. The solids were worked up as described for former polyCOOH *f*-INT-WS₂ to obtain 1.3 g of functional product.

2.6 Preparation of human platelet-rich plasma, platelet-poor plasma, normal pooled plasma and washed red blood cells suspension

Human platelet rich plasma (PRP), platelet poor plasma (PPP), whole blood, washed red blood cell (RBC) suspension and normal pool plasma (NPP) were prepared with blood from healthy volunteers who were free from any

medication for at least 2 weeks. Blood was collected by venipuncture into tubes containing buffered sodium citrate (109 mM, nine parts blood to one part of sodium citrate solution) (BD Vacutainer®). The study protocol was in accordance with the Declaration of Helsinki and was approved by the Medical Ethical Committee of the CHU UCL Namur (Yvoir, Belgium).

PRP was carefully prepared by centrifugation at 200g of whole blood at room temperature for 10 min. The platelet count was adjusted to 300,000 platelets/ μL and PRP was used immediately after preparation. Platelet free plasma used to adjust platelet concentration is obtained after centrifugation at 2000g in 10 min of the pellet at room temperature.

The preparation of washed RBC suspension was prepared by centrifugation of whole blood at 3000g over 5 min. The PPP is removed and used for interference assays. RBC are washed with physiological phosphate buffered saline (PBS, 6.7 mM phosphate, pH=7.4) three times with intermediate centrifugation of 3000g over 5 min. RBC are then resuspended in PBS with the same volume as PBS removed.

For NPP, a total of 47 healthy individuals were included in the study. The exclusion criteria were thrombotic and/or hemorrhagic events, antiplatelet and/or anticoagulant medication, pregnancy and uptake of drugs potentially affecting the platelet and/or coagulation factor functions during the 2 weeks prior to the blood drawn. A written informed consent was obtained from each donor. The study population displayed the following characteristics: 27 females and 20 males aged from 18 to 53 years (mean age = 25 years) with body mass index (BMI) ranging from 17.6 to 34.9 kg/m^2 (mean BMI = 22.7 kg/m^2). After collection of blood, the PPP was obtained from the supernatant fraction of the blood tubes after a double centrifugation for 15 min at 2000g at room temperature. It was immediately frozen at -80°C after centrifugation. The NPP samples were thawed and kept at 37°C just before use.

2.7 Hemolysis assays

Hemolysis assays were performed as previously described on the blood of one healthy donor [41]. Briefly, 15 μL of nanomaterial suspended in tyrode, tyrode (negative control) or triton X-100 (positive control) are added to 285 μL of whole blood or washed RBC (final NP concentration: 100 $\mu\text{g}/\text{mL}$). The suspension is incubated at room temperature on a shaking plate during 1 h. After the incubation time, the suspension is centrifuged at 10,000g over 5 min. Supernatant is read in a 96-well plate using a microplate scanning spectrophotometer XMark (Biorad, USA) at 550 nm. The percentage hemolysis was then calculated as:

$$H(\%) = \frac{(OD_{\text{sample}} - OD_{\text{tyrode}})}{(OD_{\text{TritonX-100 at 1\%}} - OD_{\text{tyrode}})} \times 100.$$

For each term of the equation, the corresponding interference was subtracted. The interference corresponds to the same conditions except that the solution does not contain RBCs. Positive (triton X – 100 at 1%) and negative (Tyrode) controls induced 100% and 0% of hemolysis, respectively. The results were expressed as mean \pm SD ($n=3$).

2.8 Light transmission aggregometry

The impact of *f*-INTs- WS_2 on induced platelet aggregation was studied using the chronometric aggregometer type 490-2D as previously reported [41]. Briefly, the reaction mixture for induced aggregation tests contained 213 or 233 μL of PRP at 300,000 platelets/ μL , with respectively 25 μL of collagen (final concentration: 190 $\mu\text{g}/\text{mL}$, calf skin, Bio/Data corporation, USA) or 5 μL of arachidonic acid (AA, final concentration: 600 μM , Calbiochem, Germany) and 12.5 μL of NPs at final concentration of 100 $\mu\text{g}/\text{mL}$. Inducers alone were also used before any experiment to check platelet reactivity. PPP was used as a reference. Data were collected with the chronolog two channel recorders at 405 nm connected to a computer.

2.9 Coagulation: calibrated thrombin generation test (cTGT)

The impact of non-functional and functional INTs- WS_2 on coagulation was studied using the calibrated thrombin generation test (cTGT) as previously reported [41]. For each experiment, a fresh mixture of fluorogenic substrate/calcium chloride buffered solution was prepared as follows: 2.6 mL of Fluo Buffer® (Thromboscope BV, The Netherlands) were mixed with 65 μL of Fluo substrate® (100 mM in DMSO, Thromboscope BV, The Netherlands). PPP-Reagent, PPP-Reagent LOW, MP-Reagent and Thrombin Calibrator (Thromboscope BV, The Netherlands) are four inducers, giving final assay concentrations of 5 pM tissue factor (TF) with 4 μM phospholipids (PL) and 16.7 mM CaCl_2 ; 1 pM TF with 4 μM PL and 16.7 mM CaCl_2 ; 4 μM PL and 16.7 mM CaCl_2 ; and 620 nM $\alpha 2$ -macroglobulin-thrombin complex, respectively. They are reconstituted with 1 mL distilled water according to the instructions provided by the manufacturer. A calibration curve was simultaneously performed using the thrombin calibrator. The acquired data were automatically processed by the software, which provided thrombin activity curves and 3 parameters based on this curve: lagtime (minutes), peak concentration (nM) and endogenous thrombin potential (ETP, $\text{nM} \times \text{minutes}$).

The INT/*f*-INTs suspensions were tested at final concentrations from 5 to 500 µg/mL. Statistical analyses were conducted with an unpaired t-test using the GraphPad Prism software (GraphPad software, v 5.01, USA).

3 Results

3.1 Fabrication and characterization of *f*-INTs-WS₂

Functional INTs-WS₂ have been effectively fabricated using the two-step surface engineering methodology described in Fig. 1 below. First and as the first critical chemical modification methodology, a strongly electrophilic VH complex arising from DMF-BrCH₂COOH reactivity has been generated in situ in the presence of starting INTs-WS₂ to provide intermediate polyacidic functional polyCOOH *f*-INTs-WS₂.

In a 2nd derivatization step, resulting chemically modified polyCOOH *f*-INTs-WS₂ nanotubes might be readily chemically activated (EDC activation) and reacted with bifunctional nucleophilic linkers of the type H₂N-link-X to provide corresponding functional polyX (polyNH₂, polySH, polyOH) *f*-INTs-WS₂ nanotubes. All these functional nanomaterials have been fully characterized by combined thermogravimetric analysis (TGA), spectroscopic FT-IR/XPS, XRD, Kaiser (NH₂ species quantification)/Ellman (SH species quantification) tests, HR-TEM and ζ potential values measurements (Table 1). All these characterization spectroscopy-based spectra/data and TEM/HR-TEM microphotographs including nanomaterials are fully detailed in the corresponding Ref. [36].

3.2 Hemocompatibility

3.2.1 Red blood cells

Absorbance spectrum of RBC suspension 10% (v/v) supernatant incubated with Triton X-100 1% (v/v) is measured. The interference of nanotubes within assay is determined at 550 nm. This interference was avoided by subtracting the OD₅₅₀ nm of INTs-WS₂/*f*-INTs-WS₂ suspended in the vehicle from the measured OD₅₅₀ nm at

the same concentration (data not shown). Measurement of absorbance at 550 nm in whole blood or washed RBC supernatant assesses the release of hemoglobin from lysis RBCs. Both non-functionalized and functionalized INTs-WS₂/*f*-INTs-WS₂ at 100 µg/mL did not induce hemolysis in whole blood (Fig. 2a) and in washed red blood cells (Fig. 2b) according to the ASTM E2524-08 standard (hemolysis ratio of all samples was below 5%) [42].

3.2.2 Platelet function

Second important parameter to be determined is the impact on platelet and in particular on platelet aggregation. At 100 µg/mL, non-functionalized and functionalized INTs-WS₂/*f*-INTs-WS₂ significantly decreased platelet aggregation induced by AA (Fig. 3b). When collagen is the inductor, only polyCOOH-*f*-INTs-WS₂ decreased significantly platelet aggregation (Fig. 3a).

3.2.3 Coagulation

Impact of *f*-INTs-WS₂ on blood coagulation was assessed through cTGT. Non-functionalized and functionalized INTs-WS₂/*f*-INTs-WS₂ impact blood coagulation when the intrinsic pathway is triggered (Fig. 4). A procoagulant effect of these nanomaterials is observed with a decrease of lagtime and an increase of peak concentration and ETP (Table 2). Based on their procoagulant activity on the intrinsic pathway, INTs-WS₂/*f*-INTs-WS₂ can be classified as follows: WS₂-NH₂ > WS₂-OH > WS₂-SH = WS₂-COOH > WS₂. Experiments with coagulation initiated by the extrinsic and common pathways demonstrated no effect of *f*-INTs-WS₂ at the exception of polyNH-*f*-INTs-WS₂ which had a procoagulant effect when common pathway is triggered (data not shown).




4 Discussion

As quite novel inorganic multi-layered nanomaterials, hydrophobic non-functional INTs-WS₂ nanotubes have been recently shown to be reactive towards a strongly

Table 1 Selected characterization (TGA) and functionality quantification data

Material	Kaiser test (mmol/g)	Ellman's test (mmol/g)	TGA—% weight loss (25–800 °C range)	ζ potential value (mV)
INTs-WS ₂	—	—	~3%	−25.0
INTs-WS ₂ COOH	—	—	11%	−34.7
INTs-WS ₂ NH ₂	0.77	—	19%	−18.9
INTs-WS ₂ SH	—	0.8	14%	−28.4
INTs-WS ₂ OH	—	—	12%	−27.2
INTs-WS ₂ OH: specific characterizing IR data	[2683–3190–3525 cm ^{−1}]: O–H stretchings set (OH organic species); 1620 and 1520 cm ^{−1} : C=O stretchings of carbonyl and amide species; 1520 cm ^{−1} : C–H stretchings (saturated aliphatic species)			

INTs, inorganic nanotubes; TGA, thermogravimetric analysis—starting INTs-WS₂ nanotubes are negatively charged (−25.0 mV) due to known OH-based defects arising from industrial nanofabrication step



electrophilic acidic VH complex arising from both DMF/Br-CH₂COOH reagents that enabled stable covalent nanotube surface chemical engineering/chemical modification by a corresponding polyCOOH shell (polyCOOH *f*-INTs-WS₂ nanotubes). Quite innovatively while using specific bifunctional linkers (Fig. 1), this polyacidic shell might be readily exploited via EDC activation for additional surface engineering to get a wide variety of functional *f*-INTs-WS₂ inorganic nanotubes, i.e., polyNH₂/polySH/polyOH *f*-INTs-WS₂ nanotubes [36]. It must be noticed that this innovative covalent surface engineering enables the quite effective development of any requested appropriate interfacial surface feature (surface reactive functionality, surface hydrophobicity/hydrophilicity

Table 2 Influence of INTs-WS₂/*f*-INTs-WS₂ at 100 µg/mL on thrombin generation parameters induced by the intrinsic pathway

4 µMPL	% Lagtime	% Lagtime SD	% ETP	% ETP SD	% Peak	% Peak SD
NPP	100	9	100	9	100	11
Tyrode	81	1	110	4	112	6
WS ₂	71	5	107	3	102	3
WS ₂ -COOH	58	2	114	3	113	2
WS ₂ -NH ₂	48	3	130	5	150	19
WS ₂ -OH	59	3	119	6	122	10
WS ₂ -SH	58	2	119	1	131	6

ETP, endogenous thrombin potential; NPP, normal pool plasma

Data are expressed in percentage in comparison with control (PBS) (n = 3)

balance) when incorporated into any polymeric matrix for example.

Before being used in human, biocompatibility of blood contacting devices needs to be considered to detect potential deleterious effects. Cytotoxicity studies have been initiated with TMD nanomaterials and first results are encouraging. In vitro studies have been conducted in different cellular models and do not demonstrate WS₂ nanotubes induced cytotoxicity [43, 44]. Teo Chng confirmed this safety profile and demonstrates that WS₂ is the least toxic of TMD nanomaterials [45]. In vivo studies in murine models confirmed the safety of these particles [46, 47]. In addition to cytotoxicity studies, hemocompatibility assays are also part of preclinical assessment of any biomedical device according to ISO-10993-4. Common hemocompatibility testing includes hemolysis, platelet function, and coagulation assays. The hemocompatibility of TMD is to our knowledge currently unknown. For the first time, we are reporting here the impact of non-functional/functional INTs-WS₂/*f*-INTs-WS₂ on human blood. Additionally, physicochemical properties of nanomaterials (e.g. NP shape, hydrophilicity, solubility, size, chemical composition) are linked to toxic outcomes. As a matter of direct consequence, it has been quite attractive to determine, check, and eventually confirm how such versatile surface engineering functionalization shells might influence the hemocompatibility of corresponding surface-engineered INTs-WS₂.

Hemolysis refers to the destruction of red blood cells inducing release and buildup of toxic red blood cell content (i.e. hemoglobin), which may cause potential life-threatening conditions (e.g. hepatic and renal injuries). Because of their small size, nanomaterials bind red blood cells and could induce by this way hemolysis [48]. Therefore, assessment of hemolytic potential of all medical devices in contact with blood is required. We assessed the hemolytic potential of our nanomaterials using a spectrophotometric assay suitable to study of nanomaterials (i.e.

nanoparticle/nanotube interferences need to be ruled out) [49] and demonstrated that non-functionalized and functionalized INTs-WS₂/*f*-INTs-WS₂ do not impact hemolysis on human blood and washed red blood cells (i.e. results below the 5% threshold) in accordance to ISO-10993-4. Higher levels of hemolysis are reported in experiments with washed red blood cells compared to those performed in whole blood. This difference was previously reported with silver and silica nanoparticles and is possibly related to the adsorption of human plasma biomolecules on nanoparticles, which possibly affect their hemolytic potential [41, 50]. Our results are in accordance with prior studies, which demonstrated no hemolytic effect of other TMD nanomaterials (i.e. MoSe₂ nanosheets) [51, 52]. Li et al. [53] demonstrated that coating of TiNi alloy with tungsten nanomaterial reduces hemolysis rate, which confirms the safety of such materials toward red blood cells [54]. Our results are also in accordance to prior studies that indicate that nanomaterials with anionic surface does not induce hemolysis [40]. The few effect of these nanotubes on red blood cells is reassuring for future biomedical applications.

Platelet function is also part of preclinical characterization and is an important parameter to predict impact of nanomaterials on human blood clotting. Indeed, hemostasis is regulated by both plasmatic coagulation and platelet functions and alteration of platelet functions may lead to either bleeding or thrombosis [55]. Our study assessed platelet aggregation on human blood by light transmission aggregometry following activation by two different inducers, a suitable method to assess nanomaterial potential [56]. We demonstrate nonsignificant decrease of collagen-induced platelet aggregation by *f*-INTs-WS₂ and also that same *f*-INTs-WS₂ decrease platelet aggregation when induced by arachidonic acid. To our best knowledge, no other investigated impact of such nanomaterials on platelet functions has been ever reported. Therefore, the mechanism by which

f-INTs-WS₂ induced decreased platelet aggregation is unknown. Potential hypothesis to explain this effect on platelets could be that these nanomaterials decrease agonist-induced activation. Additionally, the hydrophobicity of functional groups might be implicated in the decreased platelet aggregation. Indeed, Elbert and Hubbell have demonstrated that hydrophobic surfaces adsorb more proteins which might cause platelet adhesion and activation and therefore be responsible of blood clot [57]. This might explain why functionalization through addition of highly hydrophilic COOH groups reduces collagen-induced platelet aggregation.

As foreign materials, biomedical devices can activate human blood coagulation and dysregulate hemostasis. Human blood coagulation is characterized by a cascade of sequential proteolytic reactions which can be initiated by two pathways, the intrinsic and extrinsic ones, that both converge to thrombin generation [55]. Because coagulation is dependent to thrombin, we studied the impact of our various nanotubes on human coagulation through a thrombin generation assay, a suitable method to assess nanomaterial impact on coagulation [58] compared to routine tests, which are insensitive for small changes [55]. An additional advantage of this test is that it is performed on human plasma, a protein-containing media which limits nanomaterial interference by their coating with physiological proteins [55]. We demonstrate that non-functional INTs-WS₂ possess a procoagulant activity, which is accentuated by the functionalization feature of relating corresponding functional *f*-INTs-WS₂ nanomaterials. This procoagulant effect is mediated by activation of the intrinsic pathway while INTs-WS₂ do not affect the extrinsic pathway (data not shown). This is in line with data prior studies which indicate that nanomaterials mainly activate coagulation through intrinsic pathway [55].

The mechanism by which *f*-INTs-WS₂ induce coagulation is unknown. Numerous nanomaterial physicochemical properties are implicated in hemocompatibility and nanomaterial surface is predominant because of its interactions with plasma proteins [59]. Zeta potential is an indicator of surface charge and has been already used to predict nanomaterial effects on human health [60]. Indeed, negatively charged surfaces are expected to be more thrombogenic because contact with anionic surface initiates physiological coagulation [61]. An hypothesis suggests that the procoagulant effect of some nanomaterials is the consequence of their binding capacity with coagulation factors which induce their activation [59]. Factor XII, a factor implicated in the intrinsic pathway, is of special interest and might undergo self-activation after interaction with an anionic surface [61]. Additionally, it was already

demonstrated that anionic carbon nanotubes effectively induce human coagulation through activation of the intrinsic pathway [55]. Therefore, the anionic properties of our INTs-WS₂ may explain their prothrombotic activity. Additionally, functionalization of our INTs-WS₂ modifies surface properties and decreases zeta potential values, at the exception of NH₂-INTs-WS₂ [36]. Our study reports correlation between thrombotic potential of *f*-INTs-WS₂ and their zeta potential, at the exception of NH₂-INTs-WS₂. However, surface charges are difficult to interpret because of binding of proteins on nanomaterial surface and because zeta potential was determined in protein-free media (i.e. in water) compared to coagulation testing performed in human plasma. Finally, it is interesting to highlight that in our study, TGA weight loss correlates with TGTc peak concentration, with higher weight loss and procoagulant activity with NH₂-INTs-WS₂. TGA determines the amount of organic material bound to the *f*-INTs [36]. Therefore and together with their unique zwitterionic surface charge features (mixed positive ammonium/NH₃⁺ charges with negative OH-based defects), one might speculate that NH₂-INTs-WS₂ might better promote and bind highest amounts of organic materials to more effectively induce coagulation by better binding coagulation factors.

Tungsten disulfide nanostructures possess interesting physicochemical properties and high load bearing properties implying new opportunities in medicine [47, 62]. Potential health applications include blood-contacting and invasive devices (e.g. medical device coating, drug delivery inorganic systems, reinforcement of scaffolds for tissue engineering) [32, 46]. Moreover and quite recently, same NH₂-INTs-WS₂ nanomaterials have been successfully derivatized by nanotube surface-localised C-quantum dots towards both (i) cancer cell fluorescence imaging/investigation, and (ii) quite effective photothermal cell killing capability (PTT therapy potentiality), [63] thus opening a quite attractive future field of PTT cancer therapy by such non-toxic inorganic nanotubes (nanoparticle theranostics) [64, 65]. Serious concerns exist about nanomaterial-induced coagulation disorders. Therefore, the analysis of nanomaterial toxic effects on human blood cells is quite mandatory. We demonstrated using in vitro models that INTs-WS₂ decrease platelet aggregation and induce a procoagulant state that is heighten by both functionalization type and level of innovative functional nanotubes. This observed effect on coagulation can be either beneficial or adverse according to its applications. Therefore, we recommend the use of the functionalized nanoparticles in applications that imply blood coagulation such as wound dressing.

Abbreviations

AA: arachidonic acid; ATR: attenuated total reflectance; BMI: body mass index; CNT: carbon nanotube; cTGT: calibrated thrombin generation test; DCM: dichloromethane; DMAP: 4-dimethylaminopyridine; DMF: dimethyl formamide; EDC: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide; ETP: endogenous thrombin potential; f-INT: functional inorganic nanotube; IF: fullerene-like; IR: infrared; MoS₂: molybdenum disulfide; NPP: normal pool plasma; PL: phospholipid; PPP: platelet-poor plasma; PRP: platelet-rich plasma; RBC: red blood cell; TEM: transmission electron microscopy; TF: tissue factor; TGA: thermogravimetric analyses; TMD: transition metal dichalcogenide; VH: Vilsmeier–Haack; WS₂: tungsten disulfide.

Authors' contributions

JL and JPL designed the study. DR and JPL fabricated and characterized the nanomaterials. LA performed the hemocompatibility experiments. LA, JL and JPL analyzed and interpreted the data. JL, HH and JPL were major contributors in writing the manuscript. All authors read and approved the final manuscript.

Author details

¹ Namur Nanosafety Centre, University of Namur, Rue de Bruxelles 61, 5000 Namur, Belgium. ² Department of Pharmacy, NARILIS, University of Namur, Namur, Belgium. ³ Department of Haematology Laboratory, Université catholique de Louvain, CHU UCL Namur, NARILIS, Yvoir, Belgium. ⁴ Department of Chemistry & Institute of Nanotechnology & Advanced Materials (BINA), Bar-Ilan University, Max & Anna Web Street, 5290002 Ramat-Gan, Israel.

Acknowledgements

Authors greatly acknowledge the Israel National Nanotechnology Initiative Focal Technology Area (FTA) organization for partial funding of this research,—FTA project "Inorganic Nanotubes: From Nanomechanics to Improved Nanocomposites" (Prof. Reshef Tenne, Weizmann Institute, FTA program coordinator).

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Funding

This project has been partially funded by the Israel National Nanotechnology Initiative Focal Technology Area (FTA) organization (FTA project "Inorganic Nanotubes: From Nanomechanics to Improved Nanocomposites").

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 15 June 2018 Accepted: 7 October 2018

Published online: 30 October 2018

References

1. S. Bertolazzi, M. Gobbi, Y. Zhao, C. Backes, P. Samori, Molecular chemistry approaches for tuning the properties of two-dimensional transition metal dichalcogenides. *Chem. Soc. Rev.* **47**(17), 6845–6888 (2018)
2. Z. Cai, B. Liu, X. Zou, H.-M. Cheng, Chemical vapor deposition growth and applications of two-dimensional materials and their heterostructures. *Chem. Rev.* **118**(13), 6091–6133 (2018)
3. R. Dong, I. Kuljanishvili, Review article: progress in fabrication of transition metal dichalcogenides heterostructure systems. *J. Vac. Sci. Technol.* **35**(3), 030803 (2017)
4. A. Eftekhari, Tungsten dichalcogenides (WS₂, WSe₂, and WTe₂): materials chemistry and applications. *J. Mater. Chem.* **5**(35), 18299–18325 (2017)
5. J. Ping, Z. Fan, M. Sindoro, Y. Ying, H. Zhang, Recent advances in sensing applications of two-dimensional transition metal dichalcogenide nanosheets and their composites. *Adv. Func. Mater.* **27**(19), 1605817 (2017)
6. M. Samadi, N. Sarikhani, M. Zirak, H. Zhang, H.-L. Zhang, A.Z. Moshfegh, Group 6 transition metal dichalcogenide nanomaterials: synthesis, applications and future perspectives. *Nanoscale Horizons*. **3**(2), 90–204 (2018)
7. J. Shi, M. Hong, Z. Zhang, Q. Ji, Y. Zhang, Physical properties and potential applications of two-dimensional metallic transition metal dichalcogenides. *Coord. Chem. Rev.* **376**, 1–19 (2018)
8. Y. Zhou, Z. Huang, R. Yang, J. Liu, Selection and screening of DNA aptamers for inorganic nanomaterials. *Chemistry* **24**(11), 2525–2532 (2018)
9. M.F.L. De Volder, S.H. Tawfik, R.H. Baughman, A.J. Hart, Carbon nanotubes: present and future commercial applications. *Science* **339**(6119), 535–539 (2013)
10. R. Tenne, M. Redlich, Recent progress in the research of inorganic fullerene-like nanoparticles and inorganic nanotubes. *Chem. Soc. Rev.* **39**(5), 1423–1434 (2010)
11. H.Y. Zhao, S.T. Oyama, E.D. Naeemi, Hydrogen storage using heterocyclic compounds: the hydrogenation of 2-methylthiophene. *Catal. Today* **149**(1–2), 172–184 (2010)
12. B. Radisavljevic, A. Radenovic, J. Brivio, V. Giacometti, A. Kis, Single-layer MoS₂ transistors. *Nat. Nanotechnol.* **6**(3), 147–150 (2011)
13. T. Hübert, H. Hattermann, M. Griepentrog, Sol–gel-derived nanocomposite coatings filled with inorganic fullerene-like WS₂. *J. Sol-Gel. Sci. Technol.* **51**(3), 295–300 (2009)
14. T. Polcar, A. Noss, M. Evaristo, A. Cavaleiro, Nanocomposite coatings of carbon-based and transition metal dichalcogenides phases—a review. *Rev. Adv. Mater. Sci.* **15**(2), 118–126 (2007)
15. C. Feng, L. Huang, Z. Guo, H. Liu, Synthesis of tungsten disulfide (WS₂) nanoflakes for lithium ion battery application. *Electrochem. Commun.* **9**(1), 119–122 (2007)
16. G.L. Frey, K.J. Reynolds, R.H. Friend, H. Cohen, Y. Feldman, Solution-processed anodes from layer-structure materials for high-efficiency polymer light-emitting diodes. *J. Am. Chem. Soc.* **125**(19), 5998–6007 (2003)
17. A. Katz, M. Redlich, L. Rapoport, H.D. Wagner, R. Tenne, Self-lubricating coatings containing fullerene-like WS₂ nanoparticles for orthodontic wires and other possible medical applications. *Tribol. Lett.* **21**(2), 135–139 (2006)
18. M. Ratoi, V.B. Niste, J. Walker, J. Zekonyte, Mechanism of action of WS₂ lubricant nanoadditives in high-pressure contacts. *Tribol. Lett.* **52**(1), 81–91 (2013)
19. R. Greenberg, G. Halperin, I. Etsion, R. Tenne, The effect of WS₂ nanoparticles on friction reduction in various lubrication regimes. *Tribol. Lett.* **17**(2), 179–186 (2004)
20. O. Eidelman, H. Friedman, R. Rosentsveig, A. Moshkovith, V. Perfiliev, S.R. Cohen et al., Chromium-rich coatings with WS₂ nanoparticles containing fullerene-like structure. *Nano* **06**(04), 313–324 (2011)
21. J.F. Wu, W.S. Zhai, G.F. Jie, Preparation and tribological properties of WS₂ nanoparticles modified by trioctylamine. *Proc. Inst. Mech. Eng.* **223**(4), 695–703 (2009)
22. F. Abate, V. D'Agostino, R. Di Giuda, A. Senatore, Tribological behaviour of MoS₂ and inorganic fullerene-like WS₂ nanoparticles under boundary and mixed lubrication regimes. *Tribology* **4**(2), 91–98 (2013)
23. L. Rapoport, Y. Bilik, Y. Feldman, M. Homyonfer, Hollow nanoparticles of WS₂ as potential solid-state lubricants. *Nature* **387**(6635), 791 (1997)
24. L. Rapoport, Y. Feldman, M. Homyonfer, H. Cohen, J. Sloan, J.L. Hutchison et al., Inorganic fullerene-like material as additives to lubricants: structure–function relationship. *Wear* **225**, 975–982 (1999)
25. Y.Q. Zhu, T. Sekine, K.S. Brigatti, S. Firth, R. Tenne, R. Rosentsveig et al., Shock-wave resistance of WS₂ nanotubes. *J. Am. Chem. Soc.* **125**(5), 1329–1333 (2003)
26. Y.Q. Zhu, T. Sekine, Y.H. Li, M.W. Fay, Y.M. Zhao, C.H. Patrick Poa et al., Shock-absorbing and failure mechanisms of WS₂ and MoS₂ nanoparticles with fullerene-like structures under shock wave pressure. *J. Am. Chem. Soc.* **127**(46), 16263–16272 (2005)
27. J. Cook, S. Rhyans, L. Roncase, G. Hobson, C. Luhrs, Microstructural study of IF-WS₂ failure modes. *Inorganics* **2**(3), 377–395 (2014)
28. M. Naffakh, A. Diez-Pascual, Thermoplastic polymer nanocomposites based on inorganic fullerene-like nanoparticles and inorganic nanotubes. *Inorganics* **2**(2), 291–312 (2014)

29. E. Zohar, S. Baruch, M. Shneider, H. Dodiuk, S. Kenig, R. Tenne et al., The effect of WS₂ nanotubes on the properties of epoxy-based nanocomposites. *J. Adhes. Sci. Technol.* **25**(13), 1603–1617 (2012)
30. L. Chang, H. Yang, W. Fu, N. Yang, J. Chen, M. Li et al., Synthesis and thermal stability of W/WS₂ inorganic fullerene-like nanoparticles with core-shell structure. *Mater. Res. Bull.* **41**(7), 1242–1248 (2006)
31. W. Zhang, S. Ge, Y. Wang, M.H. Rafailovich, O. Dhez, D.A. Winesett et al., Use of functionalized WS₂ nanotubes to produce new polystyrene/poly-methylmethacrylate nanocomposites. *Polymer* **44**(7), 2109–2115 (2003)
32. G. Lalwani, A.M. Henslee, B. Farshid, P. Parmar, L. Lin, Y.X. Qin et al., Tungsten disulfide nanotubes reinforced biodegradable polymers for bone tissue engineering. *Acta Biomater.* **9**(9), 8365–8373 (2013)
33. F. Xu, C. Yan, Y.T. Shyng, H. Chang, Y. Xia, Y. Zhu, Ultra-toughened nylon 12 nanocomposites reinforced with IF-WS₂. *Nanotechnology* **25**(32), 325701 (2014)
34. A. Díez-Pascual, M. Naffakh, Inorganic nanoparticle-modified poly(phenylene sulphide)/carbon fiber laminates: thermomechanical behaviour. *Materials* **6**(8), 3171–3193 (2013)
35. O. Tevet, O. Goldbart, S.R. Cohen, R. Rosentsveig, R. Popovitz-Biro, H.D. Wagner et al., Nanocompression of individual multilayered polyhedral nanoparticles. *Nanotechnology* **21**(36), 365705 (2010)
36. D. Raichman, D.A. Strawser, J.-P. Lellouche, Covalent functionalization/polycarboxylation of tungsten disulfide inorganic nanotubes (INTs-WS₂). *Nano Res.* **8**(5), 1454–1463 (2014)
37. Consumer products inventory 2014. <http://www.nanotechproject.org/cpi/search-products/?%20title=nanolub>
38. M. Naffakh, A.M. Díez-Pascual, C. Marco, G.J. Ellis, M.A. Gómez-Fatou, Opportunities and challenges in the use of inorganic fullerene-like nanoparticles to produce advanced polymer nanocomposites. *Prog. Polym. Sci.* **38**(8), 1163–1231 (2013)
39. A.R. Adini, M. Redlich, R. Tenne, Medical applications of inorganic fullerene-like nanoparticles. *J. Mater. Chem.* **21**(39), 15121 (2011)
40. M.A. Dobrovolskaia, P. Aggarwal, J.B. Hall, S.E. McNeil, Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. *Mol. Pharm.* **5**(4), 487–495 (2008)
41. J. Laloy, V. Minet, L. Alpan, F. Mullier, S. Beken, O. Toussaint et al., Impact of silver nanoparticles on haemolysis, platelet function and coagulation. *Nanobiomedicine* **1**, 4 (2014)
42. J. Choi, V. Reipa, V.M. Hitchins, P.L. Goering, R.A. Malinauskas, Physico-chemical characterization and in vitro hemolysis evaluation of silver nanoparticles. *Toxicol. Sci.* **123**(1), 133–143 (2011)
43. M. Pardo, T. Shuster-Meiseles, S. Levin-Zaidman, A. Rudich, Y. Rudich, Low cytotoxicity of inorganic nanotubes and fullerene-like nanostructures in human bronchial epithelial cells: relation to inflammatory gene induction and antioxidant response. *Environ. Sci. Technol.* **48**(6), 3457–3466 (2014)
44. I. Corazzari, F.A. Deorsola, G. Gulino, E. Aldieri, S. Bensaid, F. Turci et al., Hazard assessment of W and Mo sulphide nanomaterials for automotive use. *J. Nanoparticle Res.* **16**(5), 2401 (2014)
45. W.Z. Teo, E.L. Chng, Z. Sofer, M. Pumera, Cytotoxicity of exfoliated transition-metal dichalcogenides (MoS₂, WS₂, and WSe₂) is lower than that of graphene and its analogues. *Chemistry* **20**(31), 9627–9632 (2014)
46. E.B. Goldman, A. Zak, R. Tenne, E. Kartvelishvili, S. Levin-Zaidman, Y. Neumann et al., Biocompatibility of tungsten disulfide inorganic nanotubes and fullerene-like nanoparticles with salivary gland cells. *Tissue Eng.* **21**(5–6), 1013–1023 (2015)
47. Ganzleben C, Pelsy F, Hansen SF, Corden C, Grebot B, Sobey M. Review of environmental legislation for the regulatory control of nanomaterials: final report. DG Environment of the European Commission Project Contract No 070307/2010/580540/SER/D (2011), pp. 1–244
48. T. Mocan, Hemolysis as expression of nanoparticles-induced cytotoxicity in red blood cells. *Biotechnol. Mol. Biol. Nanomed.* **1**(1), 7–12 (2013)
49. M.A. Dobrovolskaia, J.D. Clogston, B.W. Neun, J.B. Hall, A.K. Patri, S.E. McNeil, Method for analysis of nanoparticle hemolytic properties in vitro. *Nano Lett.* **8**(8), 2180–2187 (2008)
50. J. Shi, Y. Hedberg, M. Lundin, I. Odneval Wallinder, H.L. Karlsson, L. Moller, Hemolytic properties of synthetic nano- and porous silica particles: the effect of surface properties and the protection by the plasma corona. *Acta Biomater.* **8**(9), 3478–3490 (2012)
51. C. Zhong, X. Zhao, L. Wang, Y. Li, Y. Zhao, Facile synthesis of biocompatible MoSe₂ nanoparticles for efficient targeted photothermal therapy of human lung cancer. *RSC Adv.* **7**(12), 7382–7391 (2017)
52. S. Wang, K. Li, Y. Chen, H. Chen, M. Ma, J. Feng et al., Biocompatible PEGylated MoS₂ nanosheets: controllable bottom-up synthesis and highly efficient photothermal regression of tumor. *Biomaterials* **39**, 206–217 (2015)
53. H. Li, Y. Zheng, Y.T. Pei, J.T.M. de Hosson, TiNi shape memory alloy coated with tungsten: a novel approach for biomedical applications. *J. Mater. Sci. Mater. Med.* **25**(5), 1249–1255 (2014)
54. A.G. Oomen, P.M. Bos, T.F. Fernandes, K. Hund-Rinke, D. Boraschi, H.J. Byrne et al., Concern-driven integrated approaches to nanomaterial testing and assessment—report of the NanoSafety Cluster Working Group 10. *Nanotoxicology* **8**(3), 334–348 (2014)
55. E. Frohlich, Action of Nanoparticles on Platelet Activation and Plasmatic Coagulation. *Curr. Med. Chem.* **23**(5), 408–430 (2016)
56. J. Laloy, F. Mullier, L. Alpan, J. Mejia, S. Lucas, B. Chatelain et al., A comparison of six major platelet functional tests to assess the impact of carbon nanomaterials on platelet function: a practical guide. *Nanotoxicology* **8**(2), 220–232 (2014)
57. D.L. Elbert, J.A. Hubbell, Surface treatments of polymers for biocompatibility. *Annu. Rev. Mater. Sci.* **26**(1), 365–394 (1996)
58. J. Laloy, S. Robert, C. Marbehan, F. Mullier, J. Mejia, J.P. Piret et al., Validation of the calibrated thrombin generation test (cTGT) as the reference assay to evaluate the procoagulant activity of nanomaterials. *Nanotoxicology* **6**(2), 213–232 (2012)
59. A.N. Ilinskaya, M.A. Dobrovolskaia, Nanoparticles and the blood coagulation system. Part II: safety concerns. *Nanomedicine* **8**(6), 969–981 (2013)
60. Y. Zhang, M. Yang, N.G. Portney, D. Cui, G. Budak, E. Ozbay et al., Zeta potential: a surface electrical characteristic to probe the interaction of nanoparticles with normal and cancer human breast epithelial cells. *Biomed. Microdevices* **10**(2), 321–328 (2008)
61. M.B. Gorbet, M.V. Sefton, Biomaterial-associated thrombosis: roles of coagulation factors, complement, platelets and leukocytes. *Biomaterials* **25**(26), 5681–5703 (2004)
62. H. Wu, R. Yang, B. Song, Q. Han, J. Li, Y. Zhang et al., Biocompatible inorganic fullerene-like molybdenum disulfide nanoparticles produced by pulsed laser ablation in water. *ACS Nano* **5**(2), 1276–1281 (2011)
63. S. Nandi, S.K. Bhunia, L. Zeiri, M. Pour, I. Nachman, D. Raichman et al., Bifunctional carbon-Dot-WS₂ nanorods for photothermal therapy and cell imaging. *Chemistry* **23**(4), 963–969 (2017)
64. J.T. Rashkow, G. Lalwani, B. Sitharaman, In vitro bioactivity of one- and two-dimensional nanoparticle-incorporated bone tissue engineering scaffolds. *Tissue Eng.* **24**(7–8), 641–652 (2018)
65. W. Wang, S. Liao, M. Liu, Q. Zhao, Y. Zhu, Polymer composites reinforced by nanotubes as scaffolds for tissue engineering. *Int. J. Polym. Sci.* **2014**, 14 (2014)